Andere Sprachen SK Biopharmaceuticals Co., Ltd.

Aktien

A326030

KR7326030004

A326030

Schlusskurs Korea S.E. Andere Börsenplätze 00:00:00 19.04.2024			% 5 Tage	% 1. Jan.
82’700 ^KRW	-2.01%		-4.61%	-17.63%

30.01.	SK Biopharmaceuticals schreibt im 4. Quartal Gewinn	MT
2023	Proteovant Therapeutics von SK Biopharmaceuticals präsentiert präklinische Daten auf der AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

SK Life Science - XCOPRI CV Receives FDA Approval for Alternate Methods of Administration That Include Crushed Tablet in Liquid Suspension Taken Orally or Through a Nasogastric Tube	12.04.
SK Life Science Celebrates Purple Day Highlighting Partnerships and Tools Designed to Empower People Living with Epilepsy in Their Journey to Achieve Zero Seizures	26.03.
SK Biopharmaceuticals Swings to Profit in Q4	30.01.
SK Group Advances Net Zero Transition via Key Renewable Energy Deal	27.11.
SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	12.10.23
Sk Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and Moped Molecular Glue Screening Platform At the 20Th Annual Discovery on Target Conference	27.09.23
SK Biopharmaceuticals Co., Ltd. acquired remaining 605 stake in ProteoVant Sciences, Inc. from Roivant Sciences Ltd..	31.08.23
Hikma and SK Biopharmaceuticals enter a strategic partnership for the Middle East and North Africa	21.08.23
South Korean Shares Close Higher on Optimism Over China's One-Year Loan Prime Rate Cut; SK Biopharma Adds 2%	21.08.23
SK Biopharmaceuticals Enters Licensing Agreement with Hikma's Middle East Division	21.08.23
SK Biopharmaceuticals Continues to Report Losses in Q2	11.08.23
SK Biopharmaceuticals Assembles Board of Prominent Experts to Boost Growth, Innovation	03.08.23
SK Biopharmaceuticals Forecasts $1 Billion in US Sales by 2029	19.07.23
SK Biopharmaceuticals Co., Ltd. agreed to acquire 60% interest in ProteoVant Sciences, Inc. from Roivant Sciences Ltd. for $47.5 million.	30.06.23
SK Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15.05.23
SK Biopharmaceuticals Narrows Loss in Q1	12.05.23
SK Biopharmaceuticals Swings to Loss in Q4	09.02.23
SK to Showcase 40 Carbon Reduction Technologies at CES 2023	21.12.22
SK Biopharmaceuticals' Anti-Epilepsy Treatment Cenobamate Approve for Sale in France	12.12.22
SK Biopharmaceuticals' Partner Angelini Pharma Launches Cenobamate in France	09.12.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen SK Biopharmaceuticals Co., Ltd.

Aktien

A326030

KR7326030004

A326030

Andere Sprachen

Filter